ÌÇÐÄ´«Ã½

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ÌÇÐÄ´«Ã½

Dry Age-Related Macular Degeneration: Distribution of Visual Acuity and Progression Risk in a Large Registry.

ÌÇÐÄ´«Ã½

Dry Age-Related Macular Degeneration: Distribution of Visual Acuity and Progression Risk in a Large Registry. Ophthalmology and therapy Leng, T., Schwartz, J., Nimke, D., Gallivan, M., Fevrier, H., Rozario, N., Schultz, N. M. 2022

Abstract

INTRODUCTION: Understanding the progression to geographic atrophy (GA) in late dry age-related macular degeneration (dAMD) can support development opportunities for dAMD treatments. We characterized dAMD by distribution of visual acuity (VA) categories and evaluated VA progression risk by disease stage.METHODS: This retrospective observational study used data from the American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) to identify patients diagnosed with dAMD in=1 eye from January 2016 through December 2019 (index date) with=1 visit and =1 VA measurement recorded post-index date. Patients were followed until the date of last visit, last contribution for diagnosing provider, or diagnosis of neovascular AMD post-index. Models were utilized to describe the distribution of VA categories and progression to worsening VA.RESULTS: Data from 593,277patients were analyzed. At baseline, 64.4% had mild disease, 29.4% intermediate, and 2.9%/3.3% had GA with/without subfoveal involvement. Most patients with mild (88.4%) and intermediate (79.7%) disease and GA without subfoveal involvement (57.1%) had baseline VA =20/63 inthestudy eye; 72.0% of patients with GA with subfoveal involvement had VA <20/63. Modeled results showed lower VAwithmore progressive stage at baseline.Annual probability ofstable dAMD based on baseline stage ranged from 82.1% (GA without) to 92.3% (GA with subfoveal involvement). Annual progression probability to GA without/with subfoveal involvement was 0.4% for mild and 5.5%forintermediate disease and from dry to neovascular AMD, 0.5% for mild and 8.0% for intermediate disease.CONCLUSIONS: Results from this analysis of a large database of electronic health records complement those from randomized trials and show that patients with more advanced dAMD have lower VA at baseline and that VA progression is generally faster with each progressive stage. Together these findings highlight the disease burden and trajectory of dAMD as well as opportunities for addressing unmet needs.

View details for

View details for